Maruyama T, Kuwata S, Koike K, Iino S, Yasuda K, Yotsuyanagi H, Moriya K, Maekawa H, Yamada H, Shibata Y, Milich D R
First Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.
Hepatology. 1998 Jan;27(1):245-53. doi: 10.1002/hep.510270137.
Precore hepatitis B virus (HBV) mutants may gradually prevail during or after seroconversion (SC) from hepatitis B e antigen (HBeAg) to hepatitis B e antigen antibody (anti-HBe) status in many chronic hepatitis B (CH-B) patients. However, patients with CH-B still produce anti-HBe more than several years after SC, and the relationship between SC and genome conversion in the precore region has not been clarified. Therefore, in patients with CH-B who had a sustained loss of HBeAg and complete remission of hepatitis after SC, the precore region was sequenced in paired serum samples from 1 year before SC to 3 years after SC. Mutant precore defective HBV DNA was found in only 6 (19%) of 31 CH-B patients who had a complete remission of hepatitis after SC. Mixed-type HBV DNA (precore wild-type and mutant-type) was found in 4 (13%) patients. Wild-type HBV DNA was found in 21 (68%) CH-B patients after SC. Longer-term follow-up of 11 CH-B patients indicated that 3 of 11 patients experienced precore genome conversion 2 to 3 years after SC. E-plus DNA or e-minus DNA was semiquantitated by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) assays before and after SC. E-plus DNA levels decreased from 10(5.56+/-1.58) to 10(2.45+/-1.61). Similarly, e-minus DNA levels declined from 10(4.25+/-1.56) to 10(1.86+/-1.37). By dot-blot assay, serum HBV DNA became negative soon after SC, as did serum HBeAg. In contrast, HBeAg-containing immune complexes were still detected after SC. Anti-HBe antibody was produced throughout SC and thereafter, as determined by a sensitive experimental assay. Therefore, we conclude that genome-conversion in the precore region is a separate event from HBeAg/anti-HBe seroconversion.
在许多慢性乙型肝炎(CH-B)患者中,乙肝病毒(HBV)前核心区突变体可能在从乙肝e抗原(HBeAg)血清学转换(SC)为乙肝e抗原抗体(抗-HBe)状态的过程中或之后逐渐占主导。然而,CH-B患者在SC后数年仍会产生抗-HBe,且前核心区SC与基因组转换之间的关系尚未阐明。因此,对于SC后HBeAg持续消失且肝炎完全缓解的CH-B患者,对其SC前1年至SC后3年的配对血清样本进行前核心区测序。在31例SC后肝炎完全缓解的CH-B患者中,仅6例(19%)发现前核心缺陷型HBV DNA突变体。4例(13%)患者发现混合型HBV DNA(前核心野生型和突变型)。SC后21例(68%)CH-B患者发现野生型HBV DNA。对11例CH-B患者进行长期随访表明,11例患者中有3例在SC后2至3年发生前核心基因组转换。在SC前后通过聚合酶链反应(PCR)和限制性片段长度多态性(RFLP)分析对E加DNA或E减DNA进行半定量。E加DNA水平从10(5.56±1.58)降至10(2.45±1.61)。同样,E减DNA水平从10(4.25±1.56)降至10(1.86±1.37)。通过斑点杂交分析,SC后血清HBV DNA很快变为阴性,血清HBeAg也是如此。相反,SC后仍可检测到含HBeAg的免疫复合物。通过灵敏的实验分析确定,抗-HBe抗体在整个SC过程及之后均有产生。因此,我们得出结论,前核心区的基因组转换是与HBeAg/抗-HBe血清学转换不同的事件。